An Exciting New Recommendation Discussed at the Equity Meeting
Last week, the World Health Organization announced they were officially endorsing the use of misoprostol for the treatment of postpartum hemorrhage (PPH). As PPH is one of the leading causes of maternal mortality, the addition of another WHO-endorsed treatment is exciting for health workers and global health professionals around the globe. Though the evidence base supporting the use of misoprostol to treat PPH has been growing, this endorsement may provide the push some providers overseas need to make this treatment choice.
For those unfamiliar, PPH is excessive bleeding (more than 500 ml) after childbirth. MCHIP works to prevent and treat PPH, both key components of the program’s maternal health strategy. You can learn more about our work on PPH here.
More on misoprostol and the announcement at http://www.misoprostol.org/File/news.php